Q1 2026 Revenue up 11% to 40B KRW
한올바이오파마
009420
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Q1 2026 Revenue: 40.031B KRW (+11% YoY)
- • Q1 2026 Operating Profit: 800M KRW
- • Q1 2026 Net Income: 300M KRW
- • Debt-to-Equity Ratio (Q1 2026): 50.18% (vs. 39.30% in prior year)
- • R&D Expenses (Q1 2026): 6.348B KRW
AI Analysis Summary
HANALL BIOPHARMA reported a strong Q1 2026 with revenue reaching 40.031B KRW, an 11% increase year-over-year, driven by key pharmaceutical products like 'Biotop' and 'Normix'. Operating profit was 800M KRW and net income was 300M KRW. The company expanded its product lineup with 'Minoxfil' and saw robust growth in 'Eligard'. Significant R&D progress was noted for autoimmune disease drugs batoclimab and imeroprubart, with positive clinical trial results and patent acquisition. The debt-to-equity ratio increased to 50.18% from 39.30% in the prior year, indicating a slight increase in financial leverage. Overall, the report shows positive operational performance and promising pipeline development.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.